A carregar...

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

A reduction in BCR-ABL1/ABL1(IS) transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients. In this study, we investigated the reliability of multiple BCR-ABL1 th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Mol Sci
Main Authors: Stella, Stefania, Zammit, Valentina, Vitale, Silvia Rita, Pennisi, Maria Stella, Massimino, Michele, Tirrò, Elena, Forte, Stefano, Spitaleri, Antonio, Antolino, Agostino, Siragusa, Sergio, Accurso, Vincenzo, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Russo, Sabina, Malato, Alessandra, Mineo, Giuseppe, Musso, Maurizio, Porretto, Ferdinando, Martino, Bruno, Di Raimondo, Francesco, Manzella, Livia, Vigneri, Paolo, Stagno, Fabio
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6539817/
https://ncbi.nlm.nih.gov/pubmed/31064152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20092226
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!